Predictive Oncology Rebrands to Axe Compute Inc. on Nasdaq

An announcement from Predictive Oncology ( (POAI) ) is now available.

On December 10, 2025, Axe Compute Inc. amended the employment agreement with CEO Raymond F. Vennare, increasing his salary and outlining bonus eligibility. On December 12, 2025, the company announced its name change to Axe Compute Inc. and began trading on Nasdaq under the ticker AGPU. The company plans to expand its operations into high-performance AI infrastructure, positioning itself as a key player in addressing the infrastructure bottleneck in AI development by utilizing the Aethir network to provide scalable GPU capacity.

The most recent analyst rating on (POAI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Spark’s Take on POAI Stock

According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.

The overall stock score is primarily impacted by the company’s poor financial performance and valuation, which are offset slightly by positive corporate events such as regaining Nasdaq compliance and securing substantial private placements. The technical analysis indicates bearish momentum, further weighing down the score.

To see Spark’s full report on POAI stock, click here.

More about Predictive Oncology

Axe Compute Inc., formerly known as Predictive Oncology Inc., operates in the AI-driven drug discovery industry and is expanding into high-performance enterprise AI infrastructure. The company aims to address the growing demand for scalable compute capacity across AI workloads by leveraging its access to the Aethir network, which provides decentralized global infrastructure and GPU services.

Average Trading Volume: 105,515

Technical Sentiment Signal: Sell

Current Market Cap: $20.09M

See more data about POAI stock on TipRanks’ Stock Analysis page.